Since 2019 Cofounder Samsara Therapeutics, Delaware, US
Since 2013 Direktor Cell Biology platform, Gustave Roussy Cancer Center, Villejuif, France
Since 2012 CR1, INSERM U1138 (Kroemerlab), Centre de Recherche Des Cordeliers, Paris, France
2010-2011 INSERM PostDoctoral fellow, Gustave Roussy Cancer Center, Villejuif, France
2008-2010 EMBO fellow, INSERM U848 (Kroemerlab), Gustave Roussy Cancer Center, Villejuif, France
2007 Max Planck PostDoctoral fellow, Max Planck Insitute for Infection Biology, Berlin, Germany
Until 2006 PhD Max Planck Insitute for Infection Biology, Humboldt University, Berlin, Germany
Dr. Oliver Kepp graduated from Humboldt University Berlin and obtained a PhD degree in Molecular Biology for his work on "Host cell apoptosis" conducted at the Max Planck Institute for Infection Biology. Following he was a Max Planck postdoctoral research fellow and in 2007 joined the INSERM team headed by Prof. Guido Kroemer at the Gustave Roussy Cancer Center (GRCC) as an EMBO postdoc fellow. He now is a tenured researcher at INSERM and a Co-director of the BioCell automation platform at GRCC. In his work he together with his team investigates several aspects of tumor immunogenicity, focusing on systems cell biology approaches. Oliver published more than 300 scientific articles, is a member of several editorial boards, a co-founder of Samsara therapeutics and has been appointed associate director of the European academy of tumor immunology in 2019. Oliver received the prestigious Clarivate Highly Cited Researcher Award four years in a row since 2018 and has recently been ranked among the top biology and biochemistry scientists in France (#5; www.research.com)